Figure 4
From: Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells
Effect of NF-κB inhibitor Bay 11-7082 in DOX and PTX treated cells. (A-B) Effect of Bay 11–7082 on the expression of NF-κB p65 in cytoplasmic and nuclear fractions with 8 h treatment of DOX and PTX and Bay 11–7082 for 2 h. (C) Relative MDR1 mRNA of DOX and PTX treated cells. *, p < 0.05; **, p < 0.01, blank P > 0.05 (n = 3). (D) Rho-123 fluorescence ratio of DOX and PTX treated cells. *, p < 0.05; **, p < 0.01, blank, P > 0.05 (n = 3).